<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126000">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01808274</url>
  </required_header>
  <id_info>
    <org_study_id>2012-03</org_study_id>
    <nct_id>NCT01808274</nct_id>
  </id_info>
  <brief_title>Safety and Performance Study of the Edwards CENTERA Self-Expanding Transcatheter Heart Valve</brief_title>
  <acronym>CENTERA</acronym>
  <official_title>Safety and Performance Study of the Edwards CENTERA Self-Expanding Transcatheter Heart Valve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medstar Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Cardiovascular Research  Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <authority>Germany: BfArM (Federal Institute for Drugs and Medical Devices)</authority>
    <authority>Switzerland: Swissmedic (Swiss Agency for Therapeutics Products)</authority>
    <authority>France: ANSM (National Safety Agency for Drugs and Health Products)</authority>
    <authority>Italy: Ministry Health</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>The Netherlands: IGZ (The Health Care Inspectorate)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and device success of the Edwards CENTERA
      Transcatheter Heart Valve (THV) System in patients with symptomatic, severe aortic stenosis
      who are indicated for aortic valve replacement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized, prospective, multi-center safety and device success study. One
      hundred fifty (150) patients are planned to be enrolled at up to 15 participating
      investigational centers in Europe.  Patient participation will last for a minimum of 5
      years.  Patients will be assessed at the following intervals: baseline, discharge, 30 days,
      6 months, 1 year and annually thereafter through 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>All-cause mortality rate</measure>
    <time_frame>30 days post-index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>NAP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>device success (VARC II) safety endpoints (VARC II) echocardiography endpoints (VARC II)</measure>
    <time_frame>Discharge or 72 hours (whichever is longer), 30 days, 6 months, 1and 5 year post-index procedure.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>device success
absence of procedural mortality AND correct positioning of a single THV and intended performance of the THV
safety endpoints
composite of mortality, and major complications including THV-related dysfunction major bleeds MI new conduction abnormality new onset of AF time-related valve safety compo-site of valve structural deterioration composite of all-cause mortality, all stroke, re-hospitalization for valve-related symptoms or worsening CHF rehospitalization for valve cause NYHA class 6 MWT QoL Hospital length of stay
echocardiography endpoints
PVL &amp; total valve regurgitation prostetic valve dysfunction IEOA mean aortic valve gradient structural valve deterioration LVEF</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Aortic Valve Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edwards CENTERA Self-Expanding Transcatheter Heart Valve</intervention_name>
    <description>The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).</description>
    <other_name>TAVR</other_name>
    <other_name>TAVI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. High surgical risk: STS Score ≥ 8,EuroSCORE ≥ 15.

          2. NYHA ≥ II

          3. AVA&lt; 1cm2 and mean gradient &gt; 40mmHg

          4. Heart team (including examining cardiac surgeon) agrees on eligibility including
             assessment that TAVR is appropriate

          5. Study patient is an adult of legal consent age

          6. Study patient has provided written informed consent to comply with all of the study
             procedures and follow-up visits

        Exclusion Criteria:

          1. Acute myocardial infarction ≤ 30 days before the intended treatment

          2. Untreated clinically significant coronary artery disease requiring revascularization.

          3. Aortic valve is a congenital unicuspid or congenital bicuspid valve.

          4. Mixed aortic valve disease (with predominant aortic regurgitation)

          5. Preexisting bioprosthetic valve or ring in any position

          6. Leukopenia, anemia, thrombocytopenia

          7. Non-valvular hypertrophic cardiomyopathy with or without obstruction

          8. Severe ventricular dysfunction with LVEF &lt; 20%

          9. Echocardiographic evidence of intracardiac mass, thrombus or vegetation

         10. Active upper GI bleeding within 30 days prior to procedure

         11. Known contraindication or hypersensitivity to all anticoagulation regimens, or
             inability to be anticoagulated for the study procedure

         12. Native aortic annulus size &lt; 18 mm or &gt; 27 mm as measured by CT

         13. Clinically (by neurologist) or neuroimaging confirmed stroke or TIA within 180 days
             of the procedure

         14. Renal insufficiency (creatinine &gt; 3.0 mg/dL) and/or renal replacement therapy at the
             time of screening

         15. Estimated life expectancy &lt; 24 months

         16. Expectation that patient will not improve despite treatment of aortic stenosis

         17. Currently participating in an investigational drug or another device study

         18. Active bacterial endocarditis within 180 days of procedure

         19. Access vessel characteristics that would preclude safe placement of a 16F sheath,
             which may include any of the following: severe obstructive calcification, severe
             tortuosity

         20. Known hypersensitivity to nitinol (nickel or titanium)

         21. PCI within one month (30 days) prior to the TAVI procedure

         22. Emergency procedures within one month (30 days) prior to the TAVI procedure.

         23. Severe mitral insufficiency
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Windecker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inselspital Bern (Switzerland)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Mohr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leipzig, Rhön Herzentrum (Germany)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jodi Akin, MSN</last_name>
    <phone>949-250-2730</phone>
    <email>jodi_akin@edwards.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ihsen Merioua, MD</last_name>
    <phone>+41 44 787 4456</phone>
    <email>ihsen_merioua@edwards.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herzzentrum Universitaet Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eberhard Grube, MD</last_name>
      <phone>+49 2241 146 1271</phone>
      <email>grubee@aol.com</email>
    </contact>
    <investigator>
      <last_name>Eberhard Grube, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St Georg Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl-Heinz Kuck, MD</last_name>
      <phone>+49 401818852305</phone>
      <email>k.kuck@asklepios.com</email>
    </contact>
    <investigator>
      <last_name>Karl-Heinz Kuck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart Center Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>042 89</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friedrich Mohr, MD</last_name>
      <phone>+49 341 865 1421</phone>
      <email>mohrf@medizin.uni-Ieipzig.de</email>
    </contact>
    <investigator>
      <last_name>Friedrich Mohr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Windecker, MD</last_name>
      <phone>+41 31 632 4497</phone>
      <email>Stephan.Windecker@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Stephan Windecker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 30, 2013</lastchanged_date>
  <firstreceived_date>March 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcatheter Aortic Valve Replacement</keyword>
  <keyword>Aortic Stenosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
